NCT07642362Recruiting
Digital Support for Multiple Myeloma Quality of Life
Digital Support for Enhancing the Quality of Life of Patients With Multiple Myeloma: An Observational, Randomized, Prospective Study (DigiMyQoL)
Source: ClinicalTrials.gov · Last updated 11 Jun 2026
Brief summary (registry, in English)
The objective of this prospective study is to investigate the quality of life of patients with multiple myeloma and the effectiveness of support provided through a personalized web-based platform. Specifically, the study will compare Patient-Reported Outcomes (PROs) and the associated improvement in side effects and quality of life achieved through appropriate personalized educational and supportive content.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 108 (estimated)
- First submitted
- 21 Apr 2026
- Start date
- 27 Feb 2025
- Primary completion date
- Mar 2028
- Lead sponsor
- CareAcross
- Diseases
- Multiple myeloma, Childhood cancers
- NCT number
- NCT07642362
What you commit to
- Study type: Interventional
- Planned participants: 108
- From 27 Feb 2025 to the primary completion date, Mar 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients that are not able to use the digital platform/application
Who the study is looking for
- Adult patients with newly diagnosed or relapsed/refractory multiple myeloma
- Patients that are able to use the digital platform/application
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Alexandra General Hospital Coordinator of this site? Confirm its status | Athens | Greece | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.